Lv4
470 积分 2024-02-04 加入
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
5天前
已完结
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
5天前
已完结
Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment
5天前
已关闭
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204
5天前
已完结
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
5天前
已完结
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
5天前
已完结
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
5天前
已完结
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase 3 KEYNOTE-006 study
5天前
已完结
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
1年前
已完结
皖公网安备34019202002308
